An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Acadia Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 9, 2024
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) will present at the 42nd Annual J.P. Morgan Healthcare Conference on January 9, 2024, at 9:00 a.m. Pacific Time. A live webcast will be accessible on the company’s website, www.acadia.com, and an archived recording will be available for approximately one month following the presentation.
Positive
None.
Negative
None.
SAN DIEGO--(BUSINESS WIRE)--
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present at the 42ndAnnual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024, at 9:00 a.m. Pacific Time, followed by a question and answer session.
A live webcast of Acadia’s presentation will be accessible on the company’s website, www.acadia.com, under the investors section and an archived recording will be available on the website for approximately one month following the presentation.
About Acadia Pharmaceuticals
Acadia is advancing breakthroughs in neuroscience to elevate life. For 30 years we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialized the first and only approved therapies for hallucinations and delusions associated with Parkinson’s disease psychosis and for the treatment of Rett syndrome. Our clinical-stage development efforts are focused on treating the negative symptoms of schizophrenia, Prader-Willi syndrome, Alzheimer’s disease psychosis and neuropsychiatric symptoms in central nervous system disorders. For more information, visit us at www.acadia.com and follow us on LinkedIn and Twitter.
Media Contact:
Acadia Pharmaceuticals Inc.
Deb Kazenelson
(818) 395-3043
media@acadia-pharm.com
Investor Contact:
Acadia Pharmaceuticals Inc.
Al Kildani
(858) 261-2872
ir@acadia-pharm.com
Acadia Pharmaceuticals Inc.
Jessica Tieszen
(858) 261-2950
ir@acadia-pharm.com
Source: Acadia Pharmaceuticals Inc.
FAQ
When will Acadia Pharmaceuticals Inc. present at the 42nd Annual J.P. Morgan Healthcare Conference?
Acadia Pharmaceuticals Inc. will present at the 42nd Annual J.P. Morgan Healthcare Conference on January 9, 2024, at 9:00 a.m. Pacific Time.
Where can I access the live webcast of Acadia Pharmaceuticals Inc.'s presentation?
The live webcast of Acadia Pharmaceuticals Inc.'s presentation will be accessible on the company’s website, www.acadia.com, under the investors section.
How long will the archived recording of Acadia Pharmaceuticals Inc.'s presentation be available?
The archived recording of Acadia Pharmaceuticals Inc.'s presentation will be available on the website for approximately one month following the presentation.
acadia pharmaceuticals (nasdaq: acad) is a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in related central nervous system (cns) disorders. all of acadia's product candidates emanate from internal discoveries. we believe that they offer innovative therapeutic approaches that may provide significant advantages relative to current therapies. acadia’s history is rooted in science and strong leadership in cns research. our proprietary drug discovery platform has led to a portfolio of drug candidates with large unmet needs. since the beginning, we have been dedicated to discovering, developing and commercializing innovative therapies that improve the lives of patients suffering from such disorders. acadia is headquartered in san diego. the city represents the second largest biotechnology industry cluster in the united states, home to over 400 companies, as well as the salk institute for biological studies